Max Hasmann

3.0k total citations · 1 hit paper
49 papers, 2.3k citations indexed

About

Max Hasmann is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Max Hasmann has authored 49 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 24 papers in Radiology, Nuclear Medicine and Imaging and 21 papers in Molecular Biology. Recurrent topics in Max Hasmann's work include HER2/EGFR in Cancer Research (25 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Cell Adhesion Molecules Research (7 papers). Max Hasmann is often cited by papers focused on HER2/EGFR in Cancer Research (25 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Cell Adhesion Molecules Research (7 papers). Max Hasmann collaborates with scholars based in Germany, United Kingdom and Switzerland. Max Hasmann's co-authors include Werner Scheuer, Thomas Friess, Birgit Bossenmaier, Josef Endl, Helmut Burtscher, R. Löser, Benno Rattel, Simon P. Langdon, Katja Wosikowski and Peter Mullen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Max Hasmann

47 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

2003 513 citations Max Hasmann et al. PubMed profile →

Peers

Countries citing papers authored by Max Hasmann

Since Specialization

Citations

This map shows the geographic impact of Max Hasmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hasmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hasmann more than expected).

Fields of papers citing papers by Max Hasmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Hasmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hasmann. The network helps show where Max Hasmann may publish in the future.

Co-authorship network of co-authors of Max Hasmann

This figure shows the co-authorship network connecting the top 25 collaborators of Max Hasmann. A scholar is included among the top collaborators of Max Hasmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Hasmann. Max Hasmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis 2022 ·Cancers ·(unknown), Mireia Berdiel‐Acer, Eileen Reinz, Johanna Sonntag, (unknown), Stephan Bernhardt, M. Fehling–Kaschek, Max Hasmann, Ulrike Korf, Stefan Wiemann, Jens Timmer	3
2	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer 2019 ·ESMO Open ·Juan Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas, Enriqueta Felip, Alejandro Navarro, Maria Martinez‐García, (unknown), Natasha B. Leighl, Ulrik Lassen, Morten Mau‐Sørensen, Céline Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Maja Weisser, Andrés Cervantes	22
3	Clinical development of HER3-targeting monoclonal antibodies: Perils and progress 2018 ·Cancer Treatment Reviews ·Wolfgang Jacob, Ian James, Max Hasmann, Maja Weisser	43
4	Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy 2018 ·Molecular Cancer Therapeutics ·Annie Moisan, Francesca Michielin, Wolfgang Jacob, Sven Kronenberg, (unknown), (unknown), Régine Gérard, Fethallah Benmansour, Christine McIntyre, Georgina Meneses‐Lorente, Max Hasmann, Andreas Schneeweiß, Maja Weisser, Céline Adessi	18
5	Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer 2017 ·PLoS ONE ·Denis M. Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Maja Weisser, Birgit Bossenmaier	39
6	Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation 2014 ·Pharmacology & Therapeutics ·Katharina Wartha, Frank Herting, Max Hasmann	28
7	Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3 2013 ·Carcinogenesis ·(unknown), (unknown), Vibeke Bertelsen, Max Hasmann, Inger Helene Madshus, Espen Stang	23
8	Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab 2013 ·Molecular Oncology ·Srinivas Mamidi, (unknown), Max Hasmann, (unknown), Michael Kirschfink	89
9	Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer 2012 ·British Journal of Cancer ·Andrew H. Sims, Annelien J.M. Zweemer, Yoko Nagumo, Dana Faratian, Morwenna Muir, Michael Dodds, In Hwa Um, Charlene Kay, Max Hasmann, David J. Harrison, Simon P. Langdon	38
10	Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs 2012 ·Oncogenesis ·Frauke Henjes, Christian Bender, (unknown), (unknown), Heiko Mannsperger, Christian Schmidt, Stefan Wiemann, Max Hasmann, Sebastian Aulmann, Tim Beißbarth, Ulrike Korf	63
11	Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies 2011 ·Clinical Cancer Research ·Dana Faratian, Annelien J.M. Zweemer, Yoko Nagumo, Andrew H. Sims, Morwenna Muir, Michael Dodds, Peter Mullen, (unknown), Charlene Kay, Max Hasmann, David J. Harrison, Simon P. Langdon	44
12	Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell‐by‐Cell Basis 2008 ·Annals of the New York Academy of Sciences ·Simone Diermeier‐Daucher, Max Hasmann, Gero Brockhoff	18
13	Combinations of trastuzumab with either pertuzumab or bevacizumab show higher efficacy than lapatinib-based combinations against HER2-positive breast cancer xenografts progressing on trastuzumab monotherapy 2007 ·Molecular Cancer Therapeutics ·Thomas Friess, Werner Scheuer, Max Hasmann	0
14	Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. 2006 ·PubMed ·Thomas Friess, Werner Scheuer, Max Hasmann	14
15	Cytoprotective features of selenazofurin in hematopoietic cells 2002 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Max Hasmann, (unknown), R. Pelka‐Fleischer, V. Nuessler	3
16	Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity 2002 ·Biochemical Pharmacology ·Oliver J. Stoetzer, (unknown), R. Pelka‐Fleischer, Max Hasmann, Wolfgang Hiddemann, V. Nuessler	21
17	In Vitro Efficacy of Known P-Glycoprotein Modulators Compared to Droloxifene E and Z: Studies on a Human T-Cell Leukemia Cell Line and their Resistant Variants 1998 ·Leukemia & lymphoma ·(unknown), (unknown), Frank Gieseler, Max Hasmann, (unknown), (unknown), Oliver Stötzer, H. Zwierzina, (unknown)	5
18	Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells 1995 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·André Seidel, Andreas Bunge, Birgit M. Schaefer, (unknown), (unknown), (unknown), Max Hasmann, (unknown)	42
19	Inhibition of growth‐factor‐activated proliferation by anti‐estrogens and effects on early gene expression of mcf‐7 cells 1993 ·International Journal of Cancer ·Katja Wosikowski, Willy Küng, Max Hasmann, R. Löser, Urs Eppenberger	40
20	Flow cytometric analysis of vims-infected cells and its potential use for screening antiviral agents 1990 ·Journal of Virological Methods ·Olivia Steele‐Mortimer, H. Meier-Ewert, R. Löser, Max Hasmann	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact